Madrigal Pharmaceuticals announced a worldwide exclusive licensing agreement with Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB, covering six pre‑clinical small interfering RNA (siRNA) programs targeting metabolic dysfunction‑associated steatohepatitis (MASH). The deal brings a $60 million upfront payment and unlocks potential milestone payments of up to $4.4 billion, with royalty provisions on any resulting product sales.
The agreement leverages Ribo’s GalSTAR™ liver‑targeting siRNA platform, which has been used in other collaborations, such as with Boehringer Ingelheim. By integrating these pre‑clinical assets, Madrigal aims to build a comprehensive MASH franchise that complements its first‑in‑class FDA‑approved therapy, Rezdiffra (resmetirom). CEO Bill Sibold said the company believes future patient needs will require combination approaches tailored to genetic drivers of disease, positioning Madrigal to shape the treatment landscape in this rapidly expanding market.
Madrigal’s MASH pipeline now includes more than ten programs at various development stages. In addition to Rezdiffra, the company has an oral GLP‑1 receptor agonist, MGL‑2086, and an oral DGAT‑2 inhibitor, ervogastat, among other assets. The new six pre‑clinical siRNA programs add depth to the pipeline and provide potential entry points for combination therapies that could address unmet needs in patients with moderate to advanced fibrosis.
The financial impact of the deal is significant. The upfront $60 million provides immediate cash flow, while the cumulative milestone potential of $4.4 billion reflects confidence in the pre‑clinical assets’ progression to regulatory and commercial milestones. Royalty terms will generate additional revenue streams once any licensed product reaches market, further strengthening Madrigal’s long‑term cash generation.
Market reaction to the announcement was muted, with the stock trading slightly higher on the day of the news. Analysts noted that while the deal expands the pipeline, investors are awaiting further details on the development progress of the pre‑clinical assets and the timing of milestone payments. The modest market response suggests that the transaction is viewed as a strategic step rather than an immediate revenue driver.
Management emphasized the company’s focus on cost discipline and strategic investments. Chief Medical Officer Dr. David Soergel highlighted that siRNAs offer precise liver targeting and that several genes implicated in MASH could be addressed with an mRNA‑knockdown approach. He added that the precision of siRNA gene silencing, combined with Rezdiffra, has the potential to create next‑generation MASH treatments tailored to patients’ genetic profiles.
Madrigal is scheduled to release its fourth‑quarter and full‑year 2025 financial results on February 19, 2026. The company’s recent deal‑making, including acquisitions of a DGAT2i inhibitor from Pfizer and a pre‑clinical GLP‑1 receptor agonist from CSPC Pharmaceutical, underscores its aggressive strategy to build a diversified MASH portfolio and maintain its leadership position in the market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.